AR023553A1 - Procedimiento para el diagnostico de encefalopatias espongiformes transmisibles - Google Patents

Procedimiento para el diagnostico de encefalopatias espongiformes transmisibles

Info

Publication number
AR023553A1
AR023553A1 ARP000101850A ARP000101850A AR023553A1 AR 023553 A1 AR023553 A1 AR 023553A1 AR P000101850 A ARP000101850 A AR P000101850A AR P000101850 A ARP000101850 A AR P000101850A AR 023553 A1 AR023553 A1 AR 023553A1
Authority
AR
Argentina
Prior art keywords
diagnosis
marker
transmissible spongiform
procedure
test kit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Suspension/Interruption
Application number
ARP000101850A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Vetmedica GmbH
Boehringer Ingelheim Vetmedica de C V SA
Original Assignee
Boehringer Ingelheim Vetmedica GmbH
Boehringer Ingelheim Vetmedica de C V SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Vetmedica GmbH, Boehringer Ingelheim Vetmedica de C V SA filed Critical Boehringer Ingelheim Vetmedica GmbH
Publication of AR023553A1 publication Critical patent/AR023553A1/es
Suspension/Interruption legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/555—Interferons [IFN]
    • G01N2333/57—IFN-gamma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2828—Prion diseases

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La presente se refiere a un procedimiento para el diagnostico preclínico y clínico de encefalopatías espongiformes transmisibles, caracterizado porque sedetermina la expresion modificada de una proteína marcadora. En formas de realizacionparticulare s, en el procedimiento conforme al invento la proteínamarcadora medida es la proteína de priones PrP-sen o interferon gamma (IFNgamma) o el receptor de laminina (LR) o el precursor del receptor de laminina (LRP).Se refiere también a unestuche de ens ayo con utilizacion de anticuerpos que son específicos para la proteína marcadora conforme al invento y a un estuche deensayo con utilizacion de oligonucleotidos que son capaces de hibridarse en condiciones rigurosas con el ácidonucleico que codific a la proteína marcadoraconforme al invento. Se refiere además a la utilizacion de anticuerpos u oligonucleotidos, que son específicos para las proteínas marcadoras antes mencionadas,en un procedimiento conforme al invento ytambién a la utilizacion d el estuche de ensayo para el diagnostico de encefalopatías espongiformes transmisibles.
ARP000101850A 1999-04-21 2000-04-19 Procedimiento para el diagnostico de encefalopatias espongiformes transmisibles Suspension/Interruption AR023553A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19918141A DE19918141A1 (de) 1999-04-21 1999-04-21 Verfahren zur Diagnose von übertragbaren Spongiformen Enzephalopathien

Publications (1)

Publication Number Publication Date
AR023553A1 true AR023553A1 (es) 2002-09-04

Family

ID=7905394

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000101850A Suspension/Interruption AR023553A1 (es) 1999-04-21 2000-04-19 Procedimiento para el diagnostico de encefalopatias espongiformes transmisibles

Country Status (26)

Country Link
US (2) US20030064424A1 (es)
EP (1) EP1093585A1 (es)
JP (1) JP2002543389A (es)
KR (1) KR20020021774A (es)
CN (1) CN1347501A (es)
AR (1) AR023553A1 (es)
AU (1) AU4297400A (es)
BG (1) BG106021A (es)
BR (1) BR0009843A (es)
CA (1) CA2367696A1 (es)
CO (1) CO5170446A1 (es)
CZ (1) CZ20013771A3 (es)
DE (1) DE19918141A1 (es)
EA (1) EA200101021A1 (es)
EE (1) EE200100547A (es)
HK (1) HK1043188A1 (es)
HU (1) HUP0200777A2 (es)
ID (1) ID30392A (es)
IL (1) IL145253A0 (es)
MX (1) MXPA01010546A (es)
NO (1) NO20015094L (es)
PL (1) PL350985A1 (es)
SK (1) SK15032001A3 (es)
TR (1) TR200103011T2 (es)
UY (1) UY26109A1 (es)
WO (1) WO2000065357A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0026604D0 (en) 2000-10-31 2000-12-13 Roslin Inst Edinburgh Diagnostic method
DE10108099A1 (de) * 2001-02-19 2002-09-12 Cenas Ag Verfahren zum Nachweis spezifischer Proteine und Verwendung
US20030032032A1 (en) * 2001-03-21 2003-02-13 Annelies Resink Early pre-symptomatic prion diagnostic blood test for encephalopathies
WO2002079511A1 (en) * 2001-03-30 2002-10-10 Chronix Biomedical, Inc. Diagnostic detection of nucleic acids
GB0110172D0 (en) * 2001-04-25 2001-06-20 Pa Consulting Services Improved analytical test approach for blood
WO2002097440A2 (de) * 2001-05-29 2002-12-05 Reinhold Kiehl Verfahren zur bestimmung von peptiden/proteinen, massenspektrometrie für metalle und leitfähigkeitsfeststellung
JP4093736B2 (ja) 2001-06-28 2008-06-04 株式会社日立メディコ 核磁気共鳴診断装置および診断システム
GB2379737A (en) * 2001-09-05 2003-03-19 Univ Geneve Diagnostic method for spongiform encephalopathy disease
KR20020033126A (ko) * 2002-03-08 2002-05-04 김용선 병원성 프리온 단백의 n말단의 비효소적 당화반응 최종산물의 검출에 의한 프리온 질환의 진단
WO2004050908A1 (en) * 2002-12-03 2004-06-17 Exonhit Therapeutics S.A. An early pre-symptomatic prion diagnostic blood test for encephalopathies
RU2251699C1 (ru) * 2003-09-25 2005-05-10 Киселев Всеволод Иванович Способ ранней и доклинической диагностики цервикального рака
ES2246113B1 (es) * 2003-10-31 2007-04-01 Consejo Sup. De Invest. Cientificas Procedimiento de deteccion ante-mortem de proteinas prionicas por espectroscopia infrarroja y su uso en el diagnostico de encefalopatias espongiformes transmisibles.
CA2573164A1 (en) * 2004-07-09 2006-01-26 Chronix Biomedical Detection of nucleic acids to assess risk for bovine spongiform encephalopathy
US7309589B2 (en) * 2004-08-20 2007-12-18 Vironix Llc Sensitive detection of bacteria by improved nested polymerase chain reaction targeting the 16S ribosomal RNA gene and identification of bacterial species by amplicon sequencing
EP1749892B1 (en) * 2005-08-02 2008-03-19 Roche Diagnostics GmbH Nucleotide sequence for assessing TSE
US7798645B2 (en) 2006-05-16 2010-09-21 Mark Costin Roser Visual and memory stimulating retina self-monitoring system

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5789655A (en) * 1994-05-13 1998-08-04 The Regents Of The University Of California Transgenic animals expressing artificial epitope-tagged proteins
US6008435A (en) * 1994-05-13 1999-12-28 The Regents Of The University Of California Detecting cow, sheep and human prions in a sample and transgenic mice used for same
EP1416280A3 (en) * 1995-09-14 2005-08-10 The Regents of the University of California Antibodies specific for native PrPsc
DK0891552T4 (da) * 1996-04-03 2009-05-04 Stichting Dienst Landbouwkundi Fremgangsmåde til detektion af prionsygdomme
US5834593A (en) * 1996-11-05 1998-11-10 The Regents Of The University Of California Soluble form of PrPSC which is insoluble in native form
DE19648599C1 (de) * 1996-11-23 1998-02-19 Tavira Holdings Ltd Wirkdruckgeber eines Durchflußmessers
US6221614B1 (en) * 1997-02-21 2001-04-24 The Regents Of The University Of California Removal of prions from blood, plasma and other liquids
EP0861900A1 (en) * 1997-02-21 1998-09-02 Erziehungsdirektion Of The Canton Zurich Immunological detection of prions
US5891641A (en) * 1997-02-21 1999-04-06 The Regents Of The University Of California Assay for disease related conformation of a protein
WO1998053838A2 (en) 1997-05-30 1998-12-03 Winnacker Ernst Ludwig A soluble laminin receptor precursor and methods to inhibit its interactions
US6165784A (en) * 1997-10-14 2000-12-26 The United States Of America As Represented By The Secretary Of Agriculture Antibodies for the detection of prion protein as an indication of transmissible spongiform encephalopathies
US5977324A (en) * 1998-02-20 1999-11-02 The Regents Of The University Of California Process for concentrating protein with disease-related conformation
US6528269B1 (en) * 1998-06-22 2003-03-04 Case Western Reserve University Immunological agents specific for prion protein (PRP)
US6166187A (en) * 1999-03-05 2000-12-26 The Regents Of The University Of California Method of concentrating prion proteins in blood samples
GB0119339D0 (en) * 2001-08-08 2001-10-03 Medical Res Council Method

Also Published As

Publication number Publication date
BR0009843A (pt) 2002-02-13
TR200103011T2 (tr) 2002-02-21
IL145253A0 (en) 2002-06-30
MXPA01010546A (es) 2002-06-04
CA2367696A1 (en) 2000-11-02
WO2000065357A1 (en) 2000-11-02
CN1347501A (zh) 2002-05-01
NO20015094D0 (no) 2001-10-19
KR20020021774A (ko) 2002-03-22
US20030064424A1 (en) 2003-04-03
SK15032001A3 (sk) 2002-02-05
NO20015094L (no) 2001-12-17
BG106021A (en) 2002-06-28
CO5170446A1 (es) 2002-06-27
PL350985A1 (en) 2003-02-24
US20030129667A1 (en) 2003-07-10
ID30392A (id) 2001-11-29
HK1043188A1 (zh) 2002-09-06
EP1093585A1 (en) 2001-04-25
AU4297400A (en) 2000-11-10
EE200100547A (et) 2003-02-17
EA200101021A1 (ru) 2002-04-25
UY26109A1 (es) 2000-12-29
JP2002543389A (ja) 2002-12-17
DE19918141A1 (de) 2000-10-26
CZ20013771A3 (cs) 2002-03-13
HUP0200777A2 (en) 2002-06-29

Similar Documents

Publication Publication Date Title
AR023553A1 (es) Procedimiento para el diagnostico de encefalopatias espongiformes transmisibles
Balosso et al. Disulfide-containing high mobility group box-1 promotes N-methyl-D-aspartate receptor function and excitotoxicity by activating Toll-like receptor 4-dependent signaling in hippocampal neurons
Hinz et al. α-Smooth muscle actin is crucial for focal adhesion maturation in myofibroblasts
UY29504A1 (es) Anticuerpos dirigidos contra el péptido amiloide beta y métodos que utilizan los mismos.
AR064944A1 (es) Molecula que comprende un fragmento de anticuerpo que enlaza especificamente el peptido a(beta) humano entre las posiciones de aminoacido 13 a 28, composicion que comprende dicha molecula y su uso para la preparacion de un medicamento
de Miguel–Gómez et al. Comparison of different sources of platelet-rich plasma as treatment option for infertility-causing endometrial pathologies
ECSP11011367A (es) Composición farmacéutica
BRPI0619748A8 (pt) anticorpo monoclonal, polinucleotídeo, região variável de cadeia leve, região variável de cadeia pesada, composição, mistura, métodos para produzir um anticorpo, para preparar uma composição farmacêutica ou uma mistura, de diagnóstico de uma doença ou condição associada a amilóide, para determinar o grau de carga de placa amiloidogênica em um tecido, para diagnosticar uma predisposição para uma doença ou condição, para monitorar doença residual mínima e para prever responsabilidade de um paciente, uso de um anticorpo monoclonal e/ou uma parte funcional do mesmo e/ou uma composição farmacêutica ou uma mistura, linhagem celular de hibridoma, e, kits de teste
CL2009001076A1 (es) Nanoparticulas que comprende una sustancia formadora de particulas y una proteina; composicion que comprende dichas nanoparticulas; procedimiento para suministrar una proteina a traves de la membrana hematoencefalica; uso de la composicion para profilaxis o tratar enfermedades del sistema nervioso central.
US20150202230A1 (en) Lat adapter molecule for enhanced t-cell signaling and method of use
Guo et al. Vascular neuroprotection via TrkB‐and Akt‐dependent cell survival signaling
de la Monte et al. Ethanol inhibition of aspartyl-asparaginyl-β-hydroxylase in fetal alcohol spectrum disorder: Potential link to the impairments in central nervous system neuronal migration
Ansell-Schultz et al. Reduced retromer function results in the accumulation of amyloid-beta oligomers
Adelita et al. Proteolytic processed form of CXCL12 abolishes migration and induces apoptosis in neural stem cells in vitro
CN111770762A (zh) 对由细胞内蛋白运输缺陷引起的骨骼疾病的治疗
Anni et al. Aβ1-16 controls synaptic vesicle pools at excitatory synapses via cholinergic modulation of synapsin phosphorylation
Jerman et al. OFD1 and flotillins are integral components of a ciliary signaling protein complex organized by polycystins in renal epithelia and odontoblasts
WO2015023830A1 (en) Treatment and prevention of stroke and other neurological disorders
Mizoguchi et al. Possible role of BDNF-induced microglial intracellular Ca2+ elevation in the pathophysiology of neuropsychiatric disorders
Jonsdottir et al. Endogenous aggregates of amyloidogenic cystatin C variant are removed by THP-1 cells in vitro and induce differentiation and a proinflammatory response
Rivier et al. Utrophin and dystrophin-associated glycoproteins in normal and dystrophin deficient cardiac muscle
Popp et al. Growth regulation of rat thyrocytes (FRTL-5 cells) by the secreted ectodomain of beta-amyloid precursor-like proteins
De La-Rocque Monitoring and investigating the process for cytosolic translocation after tau endocytosis
US11541101B1 (en) LEMD3 antagonizes TGF-beta-driven Smad2/3 transcription in a stiffness-dependent fashion in both the nucleus and cytosol
US20230095144A1 (en) Amyloid inhibitory peptides

Legal Events

Date Code Title Description
FB Suspension of granting procedure